eMedinewS Editorial

Health Care 41 Comments

Aldosterone antagonist in mild heart failure: New evidence

Aldosterone antagonist therapy reduces mortality in patients with moderate to severe heart failure. The EMPHASIS-HF trial demonstrated the efficacy of eplerenone in reducing mortality as well as risk of hospitalization in patients with systolic heart failure and mild symptoms.

One should use aldosterone antagonist therapy to treat heart failure in patients with NYHA functional class II HF and LVEF ≤30 percent, or NYHA functional class III to IV heart failure and LVEF <35 percent, if they can be carefully monitored for serum potassium and renal function.

Dr KK Aggarwal
Editor in Chief